memantine has been researched along with Tremor in 9 studies
Tremor: Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The current study aims to investigate the anti-tremogenic and neuroprotective effects of memantine (NMDA receptor antagonist) on the harmaline model of transient action tremor." | 7.77 | The effect of memantine in harmaline-induced tremor and neurodegeneration. ( Akman, O; Ates, N; Erturk, S; Gullu, KM; Iseri, PK; Karson, A; Kokturk, S; Yardýmoglu, M, 2011) |
| "Memantine and marijuana smoking have been found to inhibit tremor in parkinsonian patients, although the observed effects were relatively weak." | 3.96 | Neuroanatomical correlates of the inhibition of tremulous jaw movements in rats by a combination of memantine and Δ ( Frenkel, DD; Gorev, NP; Ionov, ID; Pushinskaya, II; Shpilevaya, LA, 2020) |
| " The current study aims to investigate the anti-tremogenic and neuroprotective effects of memantine (NMDA receptor antagonist) on the harmaline model of transient action tremor." | 3.77 | The effect of memantine in harmaline-induced tremor and neurodegeneration. ( Akman, O; Ates, N; Erturk, S; Gullu, KM; Iseri, PK; Karson, A; Kokturk, S; Yardýmoglu, M, 2011) |
| "The fragile X associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disease associated with the repetition of CGG triplets (55-200 CGG repetitions) in the FMR1 gene." | 2.61 | [Fragile X associated tremor/ataxia syndrome: its clinical presentation, pathology, and treatment]. ( Hagerman, RJ; Martinez-Cerdeno, V; Salcedo-Arellano, MJ, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Ionov, ID | 1 |
| Pushinskaya, II | 1 |
| Frenkel, DD | 1 |
| Gorev, NP | 1 |
| Shpilevaya, LA | 1 |
| Theeranaew, W | 1 |
| Thurtell, MJ | 1 |
| Loparo, K | 1 |
| Shaikh, AG | 1 |
| Salcedo-Arellano, MJ | 1 |
| Hagerman, RJ | 5 |
| Martinez-Cerdeno, V | 1 |
| Seritan, AL | 2 |
| Nguyen, DV | 2 |
| Mu, Y | 1 |
| Tassone, F | 1 |
| Bourgeois, JA | 2 |
| Schneider, A | 3 |
| Cogswell, JB | 2 |
| Cook, KR | 1 |
| Leehey, MA | 1 |
| Grigsby, J | 2 |
| Olichney, JM | 3 |
| Adams, PE | 1 |
| Legg, W | 1 |
| Zhang, L | 1 |
| Hagerman, PJ | 2 |
| Yang, JC | 2 |
| Niu, YQ | 2 |
| Simon, C | 2 |
| Chen, L | 1 |
| Moghaddam, ST | 1 |
| Rodriguez, A | 1 |
| Royston, A | 1 |
| Avar, M | 1 |
| Brill, R | 1 |
| Ortigas, MC | 1 |
| Olichney, J | 1 |
| Hall, DA | 1 |
| Iseri, PK | 1 |
| Karson, A | 1 |
| Gullu, KM | 1 |
| Akman, O | 1 |
| Kokturk, S | 1 |
| Yardýmoglu, M | 1 |
| Erturk, S | 1 |
| Ates, N | 1 |
| Schneider, E | 1 |
| Fischer, PA | 1 |
| Clemens, R | 1 |
| Balzereit, F | 1 |
| Fünfgeld, EW | 1 |
| Haase, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Characterization and Treatment of CNS Abnormalities in Premutation Carriers: A Double-Blind Placebo-Controlled Trial of Memantine[NCT00584948] | 94 participants (Actual) | Interventional | 2007-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The BDS-II is a 9-item, 27-point instrument that measures executive function as the capacity for behavioral and attentional self-regulation. Total score is a sum of the 9 items, with a range of 0-27, in which a higher score indicates a better performance. (NCT00584948)
Timeframe: One Year
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | One Year | |
| Memantine | 17.44 | 15.66 |
| Placebo | 16.12 | 15.72 |
The CATSYS is a set of computer assisted diagnostic instruments that can measure intention tremor, postural tremor, postural sway, manual coordination and reaction time. The tremor intensity is defined as the root mean square of accelerations, recorded in the 0.9 Hz to 15.0 Hz band during the test period. Unit is measured in m/s2 (NCT00584948)
Timeframe: 1 year
| Intervention | m/s^2 (Mean) | |
|---|---|---|
| Baseline | One Year | |
| Memantine | 1.31 | 1.77 |
| Placebo | 1.05 | 1.89 |
1 review available for memantine and Tremor
| Article | Year |
|---|---|
[Fragile X associated tremor/ataxia syndrome: its clinical presentation, pathology, and treatment].
Topics: Antidepressive Agents; Ataxia; Brain; Deep Brain Stimulation; Female; Fragile X Mental Retardation P | 2019 |
4 trials available for memantine and Tremor
| Article | Year |
|---|---|
Memantine for fragile X-associated tremor/ataxia syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Ataxia; Double-Blind Method; Female; Fragile X | 2014 |
Memantine effects on verbal memory in fragile X-associated tremor/ataxia syndrome (FXTAS): a double-blind brain potential study.
Topics: Ataxia; Brain; Double-Blind Method; Electroencephalography; Evoked Potentials; Excitatory Amino Acid | 2014 |
Memantine Improves Attentional Processes in Fragile X-Associated Tremor/Ataxia Syndrome: Electrophysiological Evidence from a Randomized Controlled Trial.
Topics: Aged; Ataxia; Attention; Cognitive Dysfunction; Drug Administration Schedule; Electroencephalography | 2016 |
[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study].
Topics: Administration, Oral; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Male; Memantine; M | 1984 |
4 other studies available for memantine and Tremor
| Article | Year |
|---|---|
Neuroanatomical correlates of the inhibition of tremulous jaw movements in rats by a combination of memantine and Δ
Topics: Animals; Dronabinol; Humans; Jaw; Memantine; Rats; Rats, Sprague-Dawley; Tremor | 2020 |
Gabapentin and memantine increases randomness of oscillatory waveform in ocular palatal tremor.
Topics: Eye Movements; Gabapentin; Humans; Memantine; Models, Neurological; Tremor | 2021 |
Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine.
Topics: Aged; Ataxia; Cyclohexanols; Drug Therapy, Combination; Female; Follow-Up Studies; Fragile X Mental | 2010 |
The effect of memantine in harmaline-induced tremor and neurodegeneration.
Topics: Animals; Cerebellum; Ethanol; Harmaline; Male; Memantine; Nerve Degeneration; Neuroprotective Agents | 2011 |